Stockscreener 앱 받기
17.97
3.04%
0.53
시장 영업 전:
18.99
1.02
+5.68%
Seaport Therapeutics Inc 주식(SPTX)의 최신 뉴스
Seaport Therapeutics (SPTX) Stock Chart and Price History 2026 - MarketBeat
SPTX Price Today: Seaport Therapeutics, Inc. Stock Price, Quote & Chart | MEXC - MEXC Exchange
Seaport Therapeutics (SPTX) Earnings Date and Reports 2026 - MarketBeat
Seaport Therapeutics Inc. (SPTX) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
IPO Tracker 2026: Kardigan stitches up $369M IPO plan - BioSpace
PureTech-founded Seaport Therapeutics advances anxiety drug after positive Phase 1 data - grafa.com
J.P. Morgan Maintains Seaport Therapeutics(SPTX.US) With Buy Rating, Maintains Target Price $42 - Moomoo
PureTech-founded Seaport reports positive GlyphAgo phase 1 data - London South East
Stifel reiterates Buy on Seaport Therapeutics stock, $30 target By Investing.com - Investing.com Nigeria
New oral anxiety drug aims to cut liver tests after early trial - Stock Titan
Stifel reiterates Buy on Seaport Therapeutics stock, $30 target - Investing.com
PureTech Highlights Seaport Progress as GlyphAgo Advances Following Positive Phase 1 Anxiety Trial Results (PRTC) - Yahoo Finance UK
PureTech Founded Entity Seaport Therapeutics Reports Positive Multiple-Ascending Dose Data from Phase 1 Proof-of-Concept Trial of GlyphAgotm in Healthy Volunteers - Lelezard
Seaport Therapeutics reports positive phase 1 data for GlyphAgo By Investing.com - Investing.com Nigeria
PureTech Founded Entity Seaport Therapeutics Reports Positive Multiple-Ascending Dose Data from Phase 1 Proof-of-Concept Trial of GlyphAgo™ in Healthy Volunteers - Yahoo Finance
Seaport Therapeutics, Inc.Common Stock (Nasdaq:SPTX) Stock Quote - FinancialContent
Positive Trial Results for Seaport Therapeutics (SPTX) in Anxiet - GuruFocus
Seaport Therapeutics reports Q1 2026 financials and pipeline progress - grafa.com
Seaport Pops on Q1 Numbers - Baystreet.ca
Seaport Therapeutics, Inc. 2026 Q1 10-Q Report: Financials, Risk Factors, and Forward-Looking Statements - Minichart
Seaport Therapeutics Reports First Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progress - BioSpace
Seaport Therapeutics Reports Strong Q1 2026 Results, Advances Neuropsychiatric Drug Pipeline, and Raises $260M in IPO - Minichart
Seaport Therapeutics reports phase 1 data for anxiety drug By Investing.com - Investing.com South Africa
Seaport Therapeutics 1Q 2026: Net loss $(25.4M), EPS $(10.34) — 10-Q Summary - TradingView
Seaport Therapeutics : Quarterly Report for Quarter Ending March 31, 2026 (Form 10-Q) - marketscreener.com
SPTX: Q1 2026 net loss rose to $25.4M; cash and investments total $212.6M post-IPO - TradingView
Earnings Flash (SPTX) Seaport Therapeutics Posts Q1 Net Loss $10.34 a Share, vs. FactSet Est of $10.64 Loss - marketscreener.com
Seaport Therapeutics reports phase 1 data for anxiety drug - Investing.com
SPTX: Clinical progress and $260M IPO extend cash runway into 2029 amid increased R&D investment - TradingView
Seaport Therapeutics reports Q1 2026 net loss of $25.4M, cash $212.6M before $260M IPO - TradingView
Earnings Flash (SPTX) Seaport Therapeutics Posts Q1 Net Loss $10.34 a Share, Vs. FactSet Est of $10.64 Loss - Moomoo
Seaport Therapeutics Reports Positive Multiple-Ascending Dose Data From Phase 1 Proof-Of-Concept Trial Of Glyphago™ In Healthy Volunteers - TradingView
Press Release: Seaport Therapeutics Reports First Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progress - Moomoo
Seaport Therapeutics Reports Positive Multiple-Ascending Dose Data from Phase 1 Proof-of-Concept Trial of GlyphAgo™ in Healthy Volunteers - The Joplin Globe
Seaport Therapeutics announces positive Phase 1 MAD results for GlyphAgo - grafa.com
SPTX Stock Price and Chart — NASDAQ:SPTX - TradingView
Seaport Therapeutics (SPTX) Stock Trends and Sentiment 2026 - MarketBeat
Citi Sticks to Its Buy Rating for Seaport Therapeutics, Inc. (SPTX) - The Globe and Mail
Seaport Therapeutics (SPTX) Stock Forecast and Price Target 2026 - MarketBeat
Citi Maintains Seaport Therapeutics(SPTX.US) With Buy Rating, Maintains Target Price $35 - Moomoo
Seaport Therapeutics to Participate in Two Upcoming Investor Conferences - Business Wire
Seaport Therapeutics, Inc.: Target Price Consensus and Analysts Recommendations | SPTX | US81221K1088 - marketscreener.com
J.P. Morgan Initiates Seaport Therapeutics(SPTX.US) With Buy Rating, Announces Target Price $42 - Moomoo
Leerink Partners Maintains Seaport Therapeutics(SPTX.US) With Buy Rating, Maintains Target Price $35 - Moomoo
Latest SPTX ETF News Today | Earnings, Events & Price Alerts - Intellectia AI
1.27%
1.43%
자본화:
|
볼륨(24시간):